Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Inform your doctor immediately if:
The following side effects may occur:
Very common side effects: can affect more than 1 in 10 patientspatients
Common side effects: can affect up to 1 in 10 patientspatients
Uncommon side effects: can affect up to 1 in 100 patientspatients
Frequency not known: cannot be estimated from available data
Dead skin cells at the injection site and ulcer at the injection site.
Reporting of side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse.Even if it is a possible side effect that does not appear in this leaflet.You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use: www.notificaRAM.esBy reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the box and on the preloaded syringe after CAD. The expiration date is the last day of the month indicated.
Do not store at a temperature above 86°F (30°C).
Medicines should not be disposed of through drains or in the trash. Dispose of the containers and medicines you no longer need at the SIGRE point of your pharmacy. If in doubt, ask your pharmacist how to dispose of the containers and medicines you no longer need. By doing so, you will help protect the environment.
Composition of Palmeux
The active principle is paliperidone.
Each pre-filled syringe of Palmeux 25 mg contains 25 mg of paliperidone (as palmitate).
Each pre-filled syringe of Palmeux 50 mg contains 50 mg of paliperidone (as palmitate).
Each pre-filled syringe of Palmeux 75 mg contains 75 mg of paliperidone (as palmitate).
Each pre-filled syringe of Palmeux 100 mg contains 100 mg of paliperidone (as palmitate).
Each pre-filled syringe of Palmeux 150 mg contains 150 mg of paliperidone (as palmitate).
The other components are:
Polisorbate 20
Macrogol
Citric acid monohydrate
Anhydrous sodium phosphate
Monohydrate dihydrogen phosphate of sodium
Sodium hydroxide (for pH adjustment)
Water for injection
Appearance of the product and contents of the package
Palmeux is a white to off-white prolonged-release injectable suspension that comes in a pre-filled syringe.
Each package contains 1 pre-filled syringe and 2 safety needles.
Marketing Authorization Holder
Amdipharm Limited
3 Burlington Road
D04 RD68 Dublin 4,
Ireland
Responsible for manufacturing
Pharmathen S.A
Dervenakion 6,
Pallini Attiki, 15351,
Greece
Ó
Pharmathen International S.A
Industrial Park Sapes,
Rodopi Prefecture, Block No 5,
Rodopi 69300,
Greece
Local Representative:
Advanz Pharma Spain S.L.U.
Paseo de la Castellana 135, 7ª
28046 Madrid (Spain)
Tel: +34 900 834 889
Last review date of this leaflet:September 2021.
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
------------------------------------------------------------------------------------------------------------------------
This information is intended solely for medical professionals or healthcare professionals and should be read in conjunction with the complete prescribing information (Summary of Product Characteristics).
The injectable suspension is for single use. It should be visually inspected to detect any foreign particles before administration. Do not use the product if the syringe is not visually free of foreign particles.
The package contains a pre-filled syringe and two safety needles (one 22 gauge 1½ inch needle and one 23 gauge 1 inch needle) for intramuscular injection
2.Select the appropriate needle.
The initial dose of Palmeux (150 mg) is administered on Day 1 in the deltoid muscle using the deltoid needle. The second initial dose of Palmeux (100 mg) is administered in the deltoid muscle one week later (Day 8) using the deltoid needle.
If the patient is switched from risperidone prolonged-release injectable to Palmeux, the first Palmeux injection (dose range 25 mg to 150 mg) can be administered in the deltoid muscle or gluteus muscle using the appropriate needle for the injection site at the time of the next scheduled injection.
Subsequent monthly maintenance injections can be administered in both the deltoid muscle and gluteus muscle using the appropriate needle for the injection site.
In the case of deltoid injection, if the patient weighs < 90 kg, use the 23 gauge 1 inch needle (25.4 mm x 0.64 mm) (needle with blue hub); if the patient weighs ≥ 90 kg, use the 22 gauge 1½ inch needle (38.1 mm x 0.72 mm) (needle with grey hub).
In the case of gluteus injection, use the 22 gauge 1½ inch needle (38.1 mm x 0.72 mm) (needle with grey hub).
3.While holding the syringe in a vertical position, remove the rubber cap from the tip with a twisting motion.
4.Open the blister pack of the safety needle to the middle. Hold the needle cover by the plastic paper of the blister pack that has just been opened. Attach the safety needle to the Luer connection of the syringe with a simple twisting motion in a clockwise direction.
5.Remove the cover by pulling it straight off, following a straight line. Do not twist the cover, as the needle may come loose from the syringe.
6.Place the syringe with the needle in a vertical position to proceed with the removal of air. Remove the air from the syringe by carefully pushing the plunger forward.
7.Inject the entire contents slowly and deeply into the selected deltoid or gluteus muscle of the patient. Do not administer by intravascular or subcutaneous route.
8.Once the injection is complete, use your finger or another finger of your hand (8a, 8b) or a flat surface (8c) to activate the needle protection system. The system is fully activated when you hear a click. Dispose of the syringe with the needle properly.
8a
8b
8c
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.